Clinical Trial Update: High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating high-dose firmonertinib in combination with bevacizumab for resectable EGFR-mutant stage II-IIIB non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Firmonertinib (firmonertinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation | Phase 2 | Status: NOT_YET_RECRUITING